Lipoxygenase Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Lipoxygenase Inhibitor (LOX Inhibitor) - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipoxygenase Inhibitor (LOX Inhibitor) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. Lipoxygenase (LOX) can catalyze fatty acid to produce a number of active metabolic products that are involved in a lot of vital diseases. For instance, type 1 and type 2 diabetes (or both), cardiovascular diseases, hypertension, renal diseases, and neurological conditions such as Alzheimer's disease and Parkinson's disease.
LOX inhibitors are developed more slowly than COX inhibitors due to a lack of specific structure of LOXs. Additionally, as a result of the coexistence of LOXs in the same organism, LOX inhibitors should be designed seriously so as to achieve the targeting effect. In particular, another regulatory domain that is different from the two known domains of the C-terminal catalytic domain and the N-terminal ?-barrel domain has been found, which will provide new ideas for the design of new LOX inhibitors.
Report Highlights
This segment of the Lipoxygenase Inhibitor (LOX Inhibitor) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lipoxygenase Inhibitor (LOX Inhibitor) Emerging Drugs
Further product details are provided in the report……..
Lipoxygenase Inhibitor (LOX Inhibitor): Therapeutic Assessment
This segment of the report provides insights about the different Lipoxygenase Inhibitor (LOX Inhibitor) drugs segregated based on following parameters that define the scope of the report, such as:
Lipoxygenase Inhibitor (LOX Inhibitor): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipoxygenase Inhibitor (LOX Inhibitor) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipoxygenase Inhibitor (LOX Inhibitor) drugs.
Lipoxygenase Inhibitor (LOX Inhibitor) Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Lipoxygenase Inhibitor (LOX Inhibitor) - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipoxygenase Inhibitor (LOX Inhibitor) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. Lipoxygenase (LOX) can catalyze fatty acid to produce a number of active metabolic products that are involved in a lot of vital diseases. For instance, type 1 and type 2 diabetes (or both), cardiovascular diseases, hypertension, renal diseases, and neurological conditions such as Alzheimer's disease and Parkinson's disease.
LOX inhibitors are developed more slowly than COX inhibitors due to a lack of specific structure of LOXs. Additionally, as a result of the coexistence of LOXs in the same organism, LOX inhibitors should be designed seriously so as to achieve the targeting effect. In particular, another regulatory domain that is different from the two known domains of the C-terminal catalytic domain and the N-terminal ?-barrel domain has been found, which will provide new ideas for the design of new LOX inhibitors.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lipoxygenase Inhibitor (LOX Inhibitor) R&D. The therapies under development are focused on novel approaches for Lipoxygenase Inhibitor (LOX Inhibitor).
This segment of the Lipoxygenase Inhibitor (LOX Inhibitor) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lipoxygenase Inhibitor (LOX Inhibitor) Emerging Drugs
- Epeleuton: Afimmune
- Tipelukast: MediciNova
Further product details are provided in the report……..
Lipoxygenase Inhibitor (LOX Inhibitor): Therapeutic Assessment
This segment of the report provides insights about the different Lipoxygenase Inhibitor (LOX Inhibitor) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Lipoxygenase Inhibitor (LOX Inhibitor)
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Lipoxygenase Inhibitor (LOX Inhibitor): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipoxygenase Inhibitor (LOX Inhibitor) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipoxygenase Inhibitor (LOX Inhibitor) drugs.
Lipoxygenase Inhibitor (LOX Inhibitor) Report Insights
- Lipoxygenase Inhibitor (LOX Inhibitor) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Lipoxygenase Inhibitor (LOX Inhibitor) drugs?
- How many Lipoxygenase Inhibitor (LOX Inhibitor) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Lipoxygenase Inhibitor (LOX Inhibitor)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipoxygenase Inhibitor (LOX Inhibitor) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lipoxygenase Inhibitor (LOX Inhibitor) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Afimmune
- MediciNova
- Mariposa Health Limited
- MedWell Laboratories
- BioElectron Technology
- CSPC Ouyi Pharmaceutical
- Veralox Therapeutics
- Qurient Therapeutics
- Epeleuton
- Tipelukast
- TA 270
- MW 001
- PTC 857
- Baicalein
- VLX 1005
- Research programme: 5-Lipoxygenase Inhibitor (LOX Inhibitor)
Introduction
Executive Summary
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lipoxygenase Inhibitor (LOX Inhibitor) - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lipoxygenase Inhibitor (LOX Inhibitor) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lipoxygenase Inhibitor (LOX Inhibitor) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Epeleuton: Afimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PTC 857: BioElectron Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
VLX 1005: Veralox Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Lipoxygenase Inhibitor (LOX Inhibitor) Key Products
Lipoxygenase Inhibitor (LOX Inhibitor)- Unmet Needs
Lipoxygenase Inhibitor (LOX Inhibitor)- Market Drivers and Barriers
Lipoxygenase Inhibitor (LOX Inhibitor)- Future Perspectives and Conclusion
Lipoxygenase Inhibitor (LOX Inhibitor) Analyst Views
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Appendix
Executive Summary
Lipoxygenase Inhibitor (LOX Inhibitor): Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lipoxygenase Inhibitor (LOX Inhibitor) - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lipoxygenase Inhibitor (LOX Inhibitor) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lipoxygenase Inhibitor (LOX Inhibitor) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Epeleuton: Afimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PTC 857: BioElectron Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
VLX 1005: Veralox Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Lipoxygenase Inhibitor (LOX Inhibitor) Key Products
Lipoxygenase Inhibitor (LOX Inhibitor)- Unmet Needs
Lipoxygenase Inhibitor (LOX Inhibitor)- Market Drivers and Barriers
Lipoxygenase Inhibitor (LOX Inhibitor)- Future Perspectives and Conclusion
Lipoxygenase Inhibitor (LOX Inhibitor) Analyst Views
Lipoxygenase Inhibitor (LOX Inhibitor) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Lipoxygenase Inhibitor (LOX Inhibitor)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Lipoxygenase Inhibitor (LOX Inhibitor)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Lipoxygenase Inhibitor (LOX Inhibitor)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Lipoxygenase Inhibitor (LOX Inhibitor)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
